A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
Status:
Not yet recruiting
Trial end date:
2026-01-31
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine how well LB54640 works and how safe it is in patients
with Hypothalamic Obesity (HO). The study will evaluate the effect of LB54640 on safety,
weight reduction, hunger, and quality of life in patients 12 years of age and older with HO.
Patients will take an oral daily dose of either LB54640 (low, middle, or high dose) or
placebo through Week 14. Eligible patients who consent to continue in the study after Week 14
will take an oral daily dose of LB54640 through Week 56.